Serine proteases, inhibitors and receptors in renal fibrosis

View Full Paper

Ask AI

Bookmark

Population

Genetically engineered mice models of renal fibrosis and patients with chronic kidney disease

Design

Review

Authors

Discussion

PAI-1/uPAR pathways merit exploration as anti-fibrotic targets in CKD; leaves open effects on clinical progression.

Population

Genetically engineered mice models of renal fibrosis (e.g., ureteral obstruction) and patients with chronic kidney disease

Intervention

Modulation of serine proteases, inhibitors (PAI-1), and receptors (uPAR)

Outcome

Renal fibrosis severity and cellular effector recruitment

Molecular pathways activated by serine proteases and PAI-1 are promising targets for future anti-fibrotic therapies in chronic kidney disease.

Allison A. Eddy (2009) studied this question.

View Full Paper

Ask AI

Bookmark